Sodium Oxybate
| Evidence Level: L2 | Predicted Indications: 6 |
Table of Contents
Sodium Oxybate: From Narcolepsy to Insomnia
One-Sentence Summary
Sodium oxybate is a central nervous system depressant (gamma-hydroxybutyrate, GHB), originally used to treat narcolepsy and narcolepsy with cataplexy. The TxGNN model predicts it may be effective for insomnia, with 3 clinical trials (only 1 directly relevant) and 12 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Narcolepsy and narcolepsy-cataplexy syndrome (the label indication text is not available, so this is taken from the knowledge-graph indication list) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.997% |
| Evidence Level | L2 |
| US Market Status | Cancelled only (all 4 authorizations are cancelled) |
| Number of NDAs | 4 (2 NDAs and 2 ANDAs; 0 currently valid) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, sodium oxybate acts on GABA-B and GHB receptors. It increases slow-wave (N3) sleep and consolidates nighttime sleep. This is consistent with its established effect on disrupted nighttime sleep in narcolepsy.
Narcolepsy involves disrupted nighttime sleep and sleep instability. Insomnia, especially sleep-maintenance insomnia, shares this feature. That makes the prediction biologically plausible. A review of sodium oxybate and baclofen (PMID 21476957) notes that GABA-B agonists shorten sleep-onset latency, increase sleep consolidation and increase slow-wave sleep.
This mechanistic link is inferred and not documented in the source record. The mechanism of GHB is also described in the literature as controversial.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00383643 | Phase 2 | Completed | 48 | Randomized, double-blind, placebo-controlled comparison of sodium oxybate (Xyrem) and zolpidem in chronic insomnia. This is the most direct evidence, but results were not available in the data compiled for this report. |
| NCT00594256 | Phase 2 | Completed | 8 | Open-label pilot of add-on Xyrem for schizophrenia and associated sleep disturbances. Only indirectly relevant to insomnia. |
| NCT01584934 | Phase 4 | Withdrawn | 0 | Placebo-controlled crossover trial in chronic fatigue syndrome. No participants were enrolled, so there are no data. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18852348 | 2008 | Open-label polysomnographic study | Archives of Neurology | Sodium oxybate for excessive daytime sleepiness and nocturnal sleep abnormalities in Parkinson disease |
| 40120323 | 2025 | Retrospective cohort | Journal of Clinical Neuroscience | Treatment patterns of narcolepsy patients on immediate-release sodium oxybate |
| 19698899 | 2009 | Review | Clinical Therapeutics | Tolerability and abuse liability of GHB for insomnia in patients with schizophrenia |
| 31526967 | 2019 | Case report | Sleep Medicine | Sodium oxybate used in a severely sleep-deprived child with EBV encephalitis and a lesion of the sleep-wake regulation system |
| 26171909 | 2015 | Systematic review | Cochrane Database of Systematic Reviews | Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in obstructive sleep apnoea |
| 18805301 | 2008 | Review | Revue Neurologique | Overview of narcolepsy with cataplexy, including sleep-maintenance insomnia |
| 37590830 | 2023 | Review | Continuum | Pediatric sleep disorders, including insomnia and narcolepsy |
| 42525367 | 2026 | Review | Neurology and Therapy | Current and emerging therapies for pediatric sleep disorders |
| 42710468 | 2026 | Not classified | Sleep Medicine | Orexin pathway modulation in narcolepsy; mentions sodium oxybate among current treatments |
No randomized trial results for sodium oxybate in insomnia appear among the publications. Most are reviews or narcolepsy-focused studies, and some concern other drugs such as pitolisant.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA214755 | Lumryz (Avadel CNS Pharmaceuticals) | Extended-release suspension | Indication text not available; cancelled |
| NDA021196 | Xyrem (Jazz Pharmaceuticals) | Solution | Indication text not available; cancelled |
| ANDA210523 | Sodium oxybate (XLCare Pharmaceuticals) | Solution | Indication text not available; cancelled |
| ANDA203631 | Sodium oxybate (Amneal Pharmaceuticals) | Solution | Indication text not available; cancelled |
Safety Considerations
- Knowledge-graph contraindications (from drug-disease edges, not label text): hypertension, epilepsy, anxiety disorder, neurotic disorder, dysthymic disorder, liver disease, gallbladder disease, substance abuse/dependence, obstructive sleep apnea, sleep apnea syndrome, congenital central hypoventilation syndrome, respiratory failure, succinic semialdehyde dehydrogenase deficiency, and parasomnia.
- Drug interactions: 48 interactions were identified. The ones listed in the data compiled for this report include many classified as Major, mainly with other central nervous system depressants:
- Opioids: morphine, codeine, hydrocodone, opium
- Sedating antihistamines: promethazine, chlorpheniramine, brompheniramine, carbinoxamine, acrivastine
- Cannabinoids: dronabinol, nabilone
- Others: ethanol, bupropion, metoclopramide, fenfluramine, sibutramine
- Moderate interactions: diazoxide, amyl nitrite, phentolamine
- Literature signals: case reports describe sleep-related eating disorder and restless legs syndrome emerging during sodium oxybate treatment. A review also discusses its abuse potential.
Please refer to the package insert for full warnings and contraindications. The label text was not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The only directly relevant trial is a small Phase 2 study (n=48) with no available results, so evidence supports L2 at most. Sodium oxybate also carries serious respiratory-depression, misuse and drug-interaction risks. All U.S. authorizations are currently cancelled, and the drug-disease contraindication list includes sleep apnea and respiratory failure, which are common in patients with insomnia. The other predicted indications (neurogenic bladder, cauda equina syndrome, Wernicke-Korsakoff syndrome, restless legs syndrome) have no supporting evidence or point to potential harm. They are not recommended for further work.
To proceed, the following is needed:
- Results of NCT00383643 (sodium oxybate vs. zolpidem in chronic insomnia)
- Package insert warnings and contraindications
- Mechanism of action data
- A risk-benefit analysis covering respiratory depression, misuse and CNS-depressant interactions
- Clarification of the current U.S. regulatory status, since all licenses are cancelled
- A larger Phase 2/3 randomized trial in insomnia with a safety plan that excludes sleep apnea and substance-use disorders
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.